# VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

> **NCT01289210** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 2 (actual)

## Conditions studied

- Low Grade B Cell Lymphoma

## Interventions

- **DRUG:** VTX-2337 plus radiotherapy

## Key facts

- **NCT ID:** NCT01289210
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2011-11
- **Final completion:** 2012-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was stopped due to slow rate of recruitment.
- **Last updated:** 2019-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01289210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01289210, "VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01289210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*